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Background: Insulin assays are affected by varying degrees of interference from anti-insulin antibodies (IAs) and by cross-reactivity 
with recombinant insulin analogues. We evaluated the usefulness of the E170 insulin assay by assessing IA effects and cross-reac-
tivity with 2 analogues.
Methods: Sera were obtained from 59 type 2 diabetes patients receiving continuous subcutaneous insulin infusion and 18 healthy 
controls. Insulin levels were determined using an E170 analyzer. To investigate the effects of IAs, we performed IA radioimmunoas-
says, and analyzed the differences between directly measured insulin (direct insulin) and polyethylene glycol (PEG)-treated insulins 
(free, IA-unbound; total, IA-bound and unbound insulin). We performed in-vitro cross-reactivity tests with insulin aspart and insulin 
glulisine.
Results: In IA-positive patients, E170 free insulin levels measured using the E170 analyzer were significantly lower than the direct 
insulin levels. The mean value of the direct/free insulin ratio and IA-bound insulin, which were calculated as the difference between 
total and free insulin, increased significantly as endogenous IA levels increased. The E170 insulin assay showed low cross-reactivi-
ties with both analogues (< 0.7%).
Conclusions: IAs interfered with E170 insulin assay, and the extent of interference correlated with the IA levels, which may be at-
tributable to the increase in IA-bound insulin, and not to an error in the assay. The E170 insulin assay may measure only endoge-
nous insulin since cross-reactivity is low. Our results suggest that the measurement of free insulin after PEG pre-treatment could be 
useful for β cell function assessment in diabetic patients undergoing insulin therapy.
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INTRODUCTION
Insulin assays are used for the diagnosis of hypoglycemia 
and may be useful in determining the pathogenesis of type 
1 and 2 diabetes. However, the previously used radio-im-
munoassays have limitations, such as varying degrees of 
cross-reactivity with endogenous insulin precursors and re-
combinant insulin analogues, and interference from anti-
insulin antibodies (IAs) [1]. These limitations have caused 
significant inter-assay variation and have led to the misin-
terpretation of laboratory results.
In the recent decades, insulin analogues have been devel-
oped through protein engineering, and the use of recombi-
nant human insulin has markedly reduced the incidence of 
insulin resistance related to IAs, compared to that related to 
poorly purified animal insulin preparations. Therefore, in-
terference from IAs is no longer thought to be serious. How-
ever, technological advancements in the mode of insulin 
administration, i.e., continuous subcutaneous insulin infu-
sion (CSII), continuous peritoneal insulin infusion (CPII), 
and insulin inhalation, may increase the risk of the IA for-
mation [2].
As recently reviewed by Sapin [3], commercially available 
insulin immunoassays still have similar limitations due to 
IAs. However, the studies themselves also had some limita-
tions, many of which stem from a simple comparison be-
tween directly measured insulin (direct insulin) and IA-un-Kim S, et al.  •  The Effects of Anti-insulin Antibodies in the Insalin Assay
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bound insulin (free insulin) levels, and few studies have de-
termined the exact cause of IA interference in the currently 
used automated insulin immunoassays.
We evaluated the usefulness of an insulin electro-chemi-
luminescence immunoassay by assessing the influences of 
IAs in targeting patients who were receiving intensive insu-
lin therapy and by estimating cross-reactivity with 2 human 
recombinant insulin analogues. To evaluate the possible 
cause of influence from IAs, we compared total insulin lev-
els (IAs-bound and unbound insulin) with direct and free 
insulin levels. We also compared the results of this assay 
with 2 other insulin immunoassays.
MATERIALS AND METHODS
1. Study subjects
Fasting blood samples from 59 type 2 diabetes patients 
receiving CSII therapy while attending Konkuk University 
Hospital diabetes out-patient clinics in Seoul between May 
and September 2008 were enrolled. To exclude the possible 
influence of the disease itself on preprocessing for IA pre-
cipitation and to determine whether healthy people have 
IAs, 18 healthy control patients attending the medical health 
examination center at the same medical institution were 
enrolled during the identical time. The diabetes group in-
cluded 36 men and 23 women and the mean age was 57.4 ± 
10.0 yr (range, 36-81). The healthy control group included 
16 men and 2 women and the mean age was 39.8 ± 9.1 yr 
(range, 19-56). The patients’ medical records were reviewed, 
not only for the results of initially requested laboratory tests, 
such as serum insulin, C-peptide, fasting glucose, and gly-
cated hemoglobin (HbA1C) levels, but also for the insulin 
therapy type they had used and the duration of CSII treat-
ment. Serum insulin and C-peptide levels were determined 
using a MODULAR analytics E170 module (Roche Diag-
nostics, Mannheim, Germany) and fasting glucose and plas  ma 
HbA1C were determined using a TBA 200FR Neo system 
(Toshiba Medical Systems Co., Ltd., Tokyo, Japan), and a 
HLC-723 G7 analyzer (Tosoh Corporation, Tokyo, Japan), 
respectively. The Institutional Review Board at the Univer-
sity of Konkuk, Seoul, Korea, approved this study.
2. Direct insulin
To distinguish the measurement of direct insulin from 
insulin pre-treated with polyethylene glycol (PEG) (free and 
total insulin), direct insulin was defined as insulin levels de-
termined using the E170 module in fasting blood samples 
without preprocessing.
3. Free and total insulins
Free insulin (IA-unbound) was determined using the E170 
insulin assay after precipitation of immune complexes with 
a 50% PEG 6000 solution [4]. The PEG solution was mixed 
with the same amount of serum sample, and then centri-
fuged at 3,000 g for 15 min at 4℃. Total insulin (bound and 
unbound) was determined using the procedure described 
by Kuzuya et al. [5], which includes the addition of HCl so-
lution before PEG precipitation to separate insulin mole-
cules from IAs. Then, only the separated IAs were precipi-
tated by PEG treatment, finally NaOH was added for neu-
tralization. Ultimately, both the free and total insulin levels 
were calculated using the dilution rates from the measured 
direct insulin levels of each supernatant. 
4. Anti-insulin antibody
To investigate the interference from IAs on insulin level 
measurement, we determined the free IA levels (not com-
bined with insulin molecules) for all subjects using radio-
immunometric assays (anti-insulin IRMA, CIS Bio Interna-
tional, Areva S.A., France). The positive threshold was set at 
5.4%, as per the manufacturer’s instructions. IA-positive pa-
tients were divided into 3 groups using arbitrarily determined 
criteria based on IA levels (Group 1, 5.4%<IA≤20.0%, N= 
21; Group 2, 20.0%<IA≤40.0%, N=16; Group 3, IA>40.0%, 
N=14). 
5. Comparison of three insulin immunoassays
Three insulin concentration measurement methods were 
compared. We used the E170 analyzer, the Advia Centaur 
Immunoassay System (Simens, Erlangen, Germany), and a 
manual INS-IRMA assay (BioSource, Nivelles, Belgium) for 
38 samples meeting the condition of sufficient residual vol-
ume among the 59 patients in the diabetes group. All the 
insulin assays were calibrated against the WHO 66/304 ref-
erence. After the E170 insulin assay, the remaining sample 
was stored at 4℃ and analyzed using the other methods 
within 24 hr, without any pre-treatment. Directly measured 
insulin levels from each method (E170, Advia Centaur, and 
IRMA) were comparatively analyzed. 
6. Analysis of cross-reactivities in E170 insulin assay
We obtained vials of 2 insulin analogues, insulin aspart 
(NovoRapid, Novo Nordisk, Bagsvaerd, Denmark) and in-
sulin glulisine (Apidra, Sanofi-Aventis, Paris, France), which 
are suitable for injection and with which our diabetes pa-
tients were most frequently treated. We serially diluted the 
analogues with 7% aqueous bovine serum albumin (BSA) 
to final concentrations of 30, 100, 300, and 1,000 mIU/L. 24     www.kjlm.org
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The insulin levels of all dilutions were measured by E170 
insulin assay, and each sample was analyzed in duplicate. 
In-vitro cross-reactivity (%) with these 2 insulin analogues 
was calculated from the ratio of the measured and nominal 
concentrations. 
7. Statistical analysis
Data were analyzed with the Predict Analytics Software 
program version 17.0 (PASW, formerly Statistical Package 
for the Social Sciences, SPSS, SPSS Inc., Chicago, IL, USA). 
The One-Sample Kolmogorov-Smirnov Goodness-of-Fit 
Test was used to assess the distribution of all variables, which 
included E170 direct, total and free insulin, IRMA and Ad-
via Centaur direct insulin, C-peptide, glucose, HbA1C, and 
CSII duration. Differences between E170 direct and free in-
sulin, and differences between E170 direct and total insulin 
were determined by using Wilcoxon matched-pair signed-
rank tests. Furthermore, differences among the E170 direct, 
total and free insulin levels and differences among the E170, 
IRMA, and Advia Centaur direct insulin levels within each 
group were determined by using Friedman two-way ANOVA 
by ranks. Differences of each variable between healthy con-
trol and diabetes mellitus (DM) patients were assessed by 
using Mann-Whitney U or Student’s t tests. Differences 
among the 5 groups (healthy control, IA negative DM group 
and IA positive group 1-3) were determined using Kruskal-
Wallis H or one-way ANOVA followed by post hoc test with 
Bonferroni correction. The Pearson’s correlation and step-
wise multiple linear regression analysis were used to find a 
correlation between IA and total insulin with other vari-
ables. Results were presented as mean ± SD unless other-
wise stated, and a P value of less than 0.05 was considered 
statistically significant.
RESULTS
1. Comparison of diabetes patients with healthy controls
All of the 18 healthy controls and 8 of the 59 diabetes pa-
tients were IA negative (range, 4.25-5.36%). The average of 
CSII durations in diabetic patients was 24.1±16.6 months 
(range, 0-84 months). Fasting insulin levels measured using 
the E170 insulin assay (E170 direct insulin), fasting glucose 
levels, and the percentage of IA and HbA1C were signifi-
cantly higher in diabetes patients than in healthy controls 
(E170 direct insulin and IA, P<0.001 by Mann-Whitney U-
test; fasting glucose and HbA1C: P<0.001 by Student’s t-test,). 
The difference in C-peptide levels between diabetes patients 
and healthy controls was not statistically significant (P= 
0.167 by Student’s t-test) (Table 1).
2. Intragroup or inter-group comparison 
IA positive diabetes patients were classified into 3 groups 
according to IA levels. To assess interference from IAs, E170 
direct and free insulin levels were compared among IA pos-
itive subjects and within each group. E170 free insulin levels 
were significantly lower than direct insulin levels for IA pos-
itive subjects (13.6±15.3 vs. 47.9±67.8, P<0.001 by Wil-
coxon test) and this decrease was observed in each of groups 
(all, P<0.005, Table 2). The mean values of the E170 direct/
free insulin ratio, which signified the extent of interference, 
and of IA-bound insulin levels, which were calculated from 
the difference between the E170 total and free insulin levels, 
gradually increased in the higher IA groups, as did the E170 
direct, total, and free insulin (Table 2). The differences among 
the 4 DM groups and total the 5 groups were statistically 
significant (all, P<0.001 by Kruskal-Wallis H test). The dif-
ferences in C-peptide and fasting glucose levels among the 
5 groups were significant (P=0.031 and 0.003, respectively 
by one-way ANOVA), but not among the 4 DM groups 
(P=0.053 and 0.183, respectively). Fasting glucose levels 
were significantly higher in the IA negative group than in 
all of the IA positive patients (P=0.046 by Student’s t test). 
The differences in HbA1C and CSII duration were not statis-
tically significant among the 5 groups (P=0.330 and 0.146, 
respectively), however, CSII duration was significantly shorter 
in the IA negative group than in all of the IA positive patients 
(10.2±16.6 vs. 26.1±15.8, P=0.027). Differences among 
E170 direct, total and free insulin levels were assessed within 
each of the 4 DM groups (Fig. 1), and were significant only 
Table 1. Clinical characteristics of 59 diabetes patients and 18 healthy con-
trols 
Variables DM patients* 
(N=59)
Healthy control 
(N=18) P value
†
Age (yr) 57.4±10.0 39.8±9.1 <0.001
Sex, male/female 36 (61.0%) / 
23 (39.0%)
16 (88.9%) / 
2 (11.1%)
0.027
Fasting insulin
‡ (mIU/L) 42.3±64.6 5.2±2.5 <0.001
IA (%) 25.5±19.8 4.7±0.3 <0.001
C-peptide (mg/mL) 2.5±1.2 2.0±0.6 0.167
Fasting glucose (mg/dL) 172.5±52.1 92.1±23.5 <0.001
HbA1C (%) 6.9±1.2 5.7±0.8 <0.001
CSII duration (month) 24.1±16.6
Values are presented as the mean±standard deviation or number of patients (%).
*DM patients are type 2 diabetes mellitus patients on continuous subcutaneous insu-
lin infusion therapy;
†P values were determined using Mann-Whitney U or Student’s 
t-test; 
‡Fasting insulin was directly measured using the E170 insulin assay without 
any pre-treatment.
Abbreviations: DM, diabetes mellitus; IA, anti-insulin antibody; CSII, continuous sub-
cutaneous insulin infusion therapy.Kim S, et al.  •  The Effects of Anti-insulin Antibodies in the Insalin Assay
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within the IA positive DM groups 2 and 3 (IA negative DM 
group, P=0.230; IA positive DM group 1, P=0.060; group 2, 
P=0.023; and group 3, P<0.001, by Friedman test). How-
ever, E170 direct insulin levels were not significantly differ-
ent from E170 total insulin levels (with  in IA-positive DM 
group 2, P=0.620; group 3, P=0.092, by Wilcoxon signed 
rank test; for all subjects, P=0.235, by paired t-test). 
3.   The relationship between IA and other variables and 
predictors of E170 total insulin 
To identify the factors related to IA, for all subjects, Pear-
son’s correlation was conducted between IA levels and other 
variables (E170 direct, total, and free insulins, E170 direct/
free insulin ratio, IA-bound insulin calculated from the dif-
ference between total and free insulin levels, C-peptide, fast-
ing glucose, HbA1C, and the duration of CSII treatment). 
Among these variables, IA-bound insulin, E170 total, direct, 
and free insulin, E170 direct/free insulin ratio, C-peptide, 
and fasting glucose (in order of correlation coefficients) were 
correlated with IA levels (Table 3).
From the stepwise multiple linear regression analysis, E170 
direct insulin (β=0.825, P<0.001) and IA level (β=0.189, 
P<0.001) were selected as independent predictive factors 
among the other variables (E170 total and free insulins, E170 
direct/free insulin ration, IA-bound insulin, C-peptide, fast-
ing glucose, HbA1C, CSII duration and IA), which influence 
E170 total insulin levels (Table 4). E170 direct insulin was 
Table 2. Data from 59 diabetes patients categorized according to anti-insulin antibody levels and 18 healthy controls
IA negative* IA positive
† 
Healthy control 
(N=18)
IA negative DM 
(N=8)
Group
‡ 1 
(5.4%<IA≤20.0%)
(N=21)
Group
‡ 2 
(20.0%<IA≤ 40.0%)
(N=16)
Group
‡ 3 
(IA>40.0%)
(N=14)
P value
§
E170 direct insulin
II (mIU/L) 5.3 ± 2.5    6.3 ± 1.7   11.2 ± 4.4   25.1 ± 18.9 128.9 ± 85.4 < 0.001
E170 free insulin
¶ (mIU/L) 4.3 ± 2.3    2.9 ± 3.0     6.4 ± 5.3   9.7 ± 7.6    28.8 ± 21.0 < 0.001
P value** <0.001 0.012 < 0.001 < 0.001 < 0.001
E170 total insulin
†† (mIU/L) 4.6 ± 2.3    4.1 ± 2.9     9.3 ± 6.3   24.4 ± 21.7 114.1 ± 64.7 < 0.001
IA-bounded insulin
‡‡ 0.2 ± 0.8    1.1 ± 1.2     2.9 ± 5.0   14.7 ± 15.4    85.3 ± 50.7 < 0.001
Direct/free insulin ratio 1.3 ± 0.3    2.3 ± 3.4     2.3 ± 2.4   3.0 ± 1.5    4.7 ± 1.8 < 0.001
C-peptide (mg/mL) 2.0 ± 0.6    2.1 ± 1.5     2.3 ± 0.8   2.3 ± 1.1    3.2 ± 1.3 0.031
Fasting glucose (mg/dL) 92.1 ± 23.5 206.5 ± 62.9   163.7 ± 49.3 161.8 ± 31.5 178.4 ± 64.0 0.003
HbA1C (%) 5.7 ± 0.8    7.8 ± 1.4     6.8 ± 1.1   6.4 ± 0.6    6.9 ± 1.4 0.330
CSII duration (month)    10.2 ± 16.6     27.8 ± 19.2   24.7 ± 13.5    25.1 ± 13.7 0.146
Values are presented as mean ± SD. 
*IA negative is anti-insulin antibody negative (IA≤5.4%); 
†IA positive is anti-insulin antibody positive (IA>5.4%); 
‡Groups 1–3 were composed of IA positive patients, which were 
divided into 3 groups according to IA levels, and the criteria for classification were arbitrarily determined; 
§P values were determined by using one-way ANOVA followed post hoc 
test with Bonferroni correction or Kruskal-Wallis H tests, which represents the differences in each variable among the 5 groups (Healthy control, IA negative DM group, and IA posi-
tive groups 1-3); 
IIE170 direct insulin levels were directly measured; 
¶E170 free insulin levels were measured after PEG precipitation, which denoted IA-unbound insulin; **P values 
were determined using Wilcoxon signed rank test, which represents the difference between E170 direct and free insulin levels within each group; 
††E170 total insulin levels were 
measured after addition of HCL (to separate insulin molecules from IAs) and PEG precipitation, which included IA-bound and unbound insulin; all of these were measured using the 
E170 insulin assay; 
‡‡IA-bound insulin levels were calculated from the difference between the E170 total and free insulin levels.
Abbreviations: IA, anti-insulin antibody; DM, diabetes mellitus; CSII, continuous subcutaneous insulin infusion therapy.
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the most significant factor and accounted for 95.6% of the 
variation in E170 total insulin (Adjusted R
2 = 0.956). As a 
result, the final regression equation was, Y (E170 total in-
sulin)=-4.823 + 0.693X1 (E170 direct insulin) + 0.535X2 (IA).
4. Comparison of three insulin immunoassays
The differences among the direct insulin levels measured 
by 3 different methods were significant (P=0.032 by Fried-
man test). The average E170 direct insulin level from the 38 
comparable patients was 41.4±65.7 mIU/L, and the average 
of Advia Centaur and IRMA direct insulin levels were 19.9 
±27.5 and 12.2±6.9 mIU/L, respectively. E170 direct insu-
lin was more correlated with Advia Centaur insulin than 
IRMA (R
2=0.763 vs. R
2=0.415, P<0.001 by simple linear 
regression analysis). Advia Centaur direct insulin levels was 
more correlated with E170 direct insulin than E170 free and 
total insulin (R
2=0.763 vs. 0.759 and, 0.663, respectively, 
P<0.001), while IRMA direct insulin was most correlated 
with E170 free insulin than E170 direct and total insulin 
(R
2=0.520 vs. 0.415 and 0.382, respectively, P<0.001).
5.   Analysis of cross-reactivity with insulin analogues in the 
E170 insulin assay
The measured concentration and calculated cross-reac-
tivity of each stratified diluted insulin analogues is summa-
rized in Table 5. The E170 insulin assay had a low cross-re-
activity of <0.7% for both insulin analogues even at the 
highest concentrations tested. 
DISCUSSION
The aim of our study was to investigate whether IAs in-
terfere with the E170 insulin assay and whether the assay 
could detect human recombinant insulin analogues, in or-
der to determine the usefulness of the E170 insulin assay.
Previous studies have reported that the measurement of 
serum insulin concentration in patients treated with insulin 
may yield unreliably high results because IAs interfere with 
insulin in both 1 or 2-site radioimmunometric assay, and 
the recently used automated immunometric assays [3, 6-9]. 
The free insulin fraction is generally regarded as the biologi-
cally active form, and the overestimation of insulin concen-
tration compared to free insulin may lead to the misinter-
pretation of a patient’s status. Therefore, there was a consen-
sus that endogenous antibodies should be removed before 
the assay. This has been achieved by precipitation with PEG, 
or ethanol, and by gel filtration [10]. However, the overesti-
mation of serum insulin concentration has not been deter-
mined in all currently available insulin assays; thus the ex-
tent and underlying causes of overestimation in each assay 
are not yet clear. Furthermore, it is generally accepted that 
human recombinant insulin analogues currently in use re-
sult in very little endogenous antibody formation compared 
to animal insulin, so the importance of preprocessing to 
eliminate antibodies before insulin measurement has greatly 
diminished over the last 2 decades.
Large, interventional studies in diabetes patients have 
shown that tight blood glucose control with intensive insu-
Table 3. Relationship between IA levels and other factors
R P value
E170 direct insulin (mIU/L) 0.812 <0.001
E170 total insulin (mIU/L) 0.856 <0.001
E170 free insulin (mIU/L) 0.680 <0.001
IA-bound insulin (mIU/L) 0.867 <0.001
E170 direct/free insulin ratio 0.569 <0.001
C-peptide (mg/mL) 0.427 <0.001
Fasting glucose (mg/dL) 0.240 0.035
HbA1C (%) 0.087 0.453
CSII duration (month) 0.178 0.232
Results are expressed as correlation coefficients and P values were calculated by us-
ing Pearson’s correlation analysis.
Abbreviations: IA, anti-insulin antibody; CSII, continuous subcutaneous insulin infu-
sion therapy.
Table 4. Relationship of variables to E170 total insulin by stepwise multiple 
linear regression analysis
Independent variables B SE β Adjusted R
2 P value
E170 direct insulin  0.693 0.038 0.825 0.956 <0.001
IA 0.535 0.128 0.189 0.967 <0.001
E170 direct insulin and IA level were selected as independent predictive factors among 
the other variables (E170 total and free insulins, E170 direct/free insulin ratio, IA-bound 
insulin, C-peptide, fasting glucose, HbA1C, CSII duration and IA), which influence E170 
total insulin levels. P values were determined using stepwise multiple linear regres-
sion analysis.
Abbreviations: B, unstandardized coefficients; β, Standardized coefficients; IA, anti-
insulin antibody.
Table 5. Cross-reactivity with recombinant human insulin analogues in the 
E170 insulin assay
Concentration, mIU/L
Detection level, mIU/L (Cross-reactivity %)
Insulin aspart (Novorapid) Insulin glulisine (Apidra)
30 <0.2 (<0.67) <0.2 (<0.67)
100 <0.2 (<0.2) <0.2 (<0.2)
300 0.312 (0.10) 0.340 (0.11)
1,000 0.341 (0.03) 0.513 (0.05)
The percentage of corss-reactivity was calculated from the ratio of the measured and 
nominal concentrations measured using the E170 insulin assay.Kim S, et al.  •  The Effects of Anti-insulin Antibodies in the Insalin Assay
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lin therapy decreases the risk of developing both micro-an-
tiopathic- and macro-angiopathic complications associated 
with hyperglycemia [11]. Based on these results, intensive 
insulin therapies, such as implantable CSII or CPII, are used 
more frequently today. Some studies have suggested that 
implantable insulin pumps may be associated with increased 
IA levels. The major causative mechanisms are insulin ag-
gregation due to storage of insulin in the pump reservoir and 
the presence of surfactant or polyethylene glycol [12, 13].
In our study, we consciously selected diabetes patients re-
ceiving insulin pump therapy, who were suspected to have 
IAs. The majority of the diabetes patients (51 of 59) were IA 
positive. Our results show interference from IAs in the E170 
insulin assay, and show that the extent of interference or 
overestimation, direct/free insulin ratio, was correlated with 
the IA level. It was also correlated with IA-bound insulin, 
which was estimated from the difference between total and 
free insulin (Table 3). Therefore, overestimation of the direct 
assay in IA positive patients may result from an increase in 
IA-bound insulin, not assay error from IAs. Our results were 
similar to those obtained in Sapin’s study [9] using the Elec-
sys (Roche diagnostics), which was the previous model of 
the E170 analyzer. However, in our understanding, our study 
takes a more theoretical approach than the others through 
comparative analysis of the relationships among direct, total 
and free insulin in the E170 insulin immunoassay.
Some results of the present study may be related to the 
insulin epitopes that are detected by the assay-specific mono-
clonal antibodies. First, our cross-reactivity results show that 
the E170 assay hardly detects the 2 human recombinant in-
sulin analogues, insulin aspart and glulisine (Table 5), and 
these results are consistent with a previous study with the 
E170 insulin immunoassay [14]. To the best of our knowl-
edge, this is the first report which determined that there is 
little cross-reactivity with insulin glulisine in the E170 insu-
lin assay. Furthermore, in our comparison of 3 insulin as-
says, the results from the E170 assay were more correlated 
with those from the Advia Centaur assay, which had a more 
similar detection method (E170 is a ECLIA and Advia Cen-
taur is a CLIA) than IRMA. IRMA yielded lower results than 
other 2 immunoassays. Finally, direct insulin as measured 
with E170 is very closed to the total insulin level (Table 4). 
Several studies have supposed that the monoclonal anti-
bodies used in the Elecsys (the previous model from the 
same manufacturer) detect a region located in the C-termi-
nus of the B chain [9, 15]. Positions B26-B30 do not impair 
antigenicity but are critical for the self-association of the in-
sulin molecule, so the C-terminus of the B chain is a major 
target for substitution to reduce human recombinant insu-
lin dimerization for rapid action in the bloodstream [16]. 
Conversely, the region between B20 and B26, the so-called 
beta-sheet hinge, is important for the binding of insulin to 
its receptor [17, 18]. If the monoclonal antibodies used in 
the E170 assay detect the C-terminus of the B chain as sug-
gested in the previous report, our above-mentioned results 
are easily explainable.
Our study suggests that the E170 insulin assay accompa-
nied by PEG pre-treatment can assess residual β-cell func-
tion in diabetes patients receiving insulin therapy. More-
over, directly measured insulin concentrations using the 
E170 insulin assay may also provide information about im-
munogenic insulin resistance, a condition in which the body 
produces insulin but does not use it properly, thus in spite 
of a high insulin concentration, glycemic control seriously 
deteriorates. Insulin resistance is a intra-cellular phenome-
non in metabolic syndrome or pre-diabetes stage of type 2 
diabetes mellitus [19]. However, immunogenic insulin re-
sistance is due to circulating IAs, and a long time ago, it was 
suggested that the difference between immunogenic insulin 
resistance and nonresistance in insulin-treated patients de-
pends primarily on the concentration of insulin-binding 
antibody [20]. High circulating levels of IAs may interfere 
with insulin pharmacokinetics, leading to worse hypergly-
cemic control as well as unexplained hypoglycemia, which 
are attributed to the ‘dumping’ of insulin from its antibody 
reservoir. In our results, IA levels were correlated with total 
insulin (Table 3), and E170 direct insulin was nearly con-
cordant with total insulin. Therefore, if the insulin concen-
tration measured using the E170 insulin assay was unreli-
ably high, and if the fasting glucose also high or unexpect-
edly low, physicians could surmise that it was due to the 
formation of IAs without determining total insulin.
From our correlation results (Table 3), IA levels were not 
related to CSII duration, but the mean CSII duration of IA 
negative DM patients was significantly shorter than that of 
IA positive DM patients (groups 1-3). Therefore, IAs might 
be produced during insulin therapy. It has been suggested 
that immunogenic insulin resistance occurs more frequently 
in patients with type 2 diabetes [21]. The duration of insulin 
therapy before the onset of severe insulin resistance has been 
reported to be from 1 month to 15 yr, and in 50-85% of pa-
tients, it occurred after less than 1 yr [22, 23]. Therefore, 
physicians should perform insulin level and fasting glucose 
tests more frequently, especially during intensive insulin 
therapy, because severe insulin resistance is often associated 
with fasting hypoglycemia and both symptomatic hypergly-
cemia, including episodes of ketoacidosis and hyperosmo-
lar coma However clinicians should be also aware of the 28     www.kjlm.org
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cross-reactivity of various insulin analogues with the assay 
used in an individual clinical laboratory because, if their in-
sulin assays detect only endogenous insulin, they will not be 
able to assess patient compliance or titrate insulin dosage.
Our study has a number of important limitations that 
need to be considered. First, there were significant differ-
ences between direct and free insulin levels in IA negative 
groups (healthy controls and IA negative DM patients). One 
possible explanation is the minimal precipitation of free in-
sulin by PEG treatment [24]; another is the unavoidable de-
lays in the time between the venipuncture and PEG treat-
ment because we targeted patients from whom we had re-
quested insulin measurement. Previous studies have found 
that the measurements change over time [10, 24], and it 
might be due to an insulin-degrading enzyme. The other 
possibility is low sensitivity caused by sample dilution, espe-
cially at low free insulin concentrations [25]. Second, we 
measured free and total insulin levels only by the E170 in-
sulin assay. Further experimental investigations are needed 
to understand the characteristics of each method, and it 
could be helpful in the standardization of insulin assays.
In conclusion, we evaluated the effects of IAs and cross-
reactivity with 2 human recombinant insulin analogues in 
the E170 insulin immunoassay. Directly measured insulin 
using the E170 assay was overestimated compared to free 
insulin, thus we confirmed that IAs interfered with the E170 
insulin assay. Both E170 direct/free ratio and IA-bound in-
sulin were correlated with IA levels. Therefore interference 
may result from the increase of IA-bound insulin, not from 
an assay error from IAs. The E170 insulin assay is thought 
to measure only human endogenous insulin because of low 
cross-reactivity with recombinant insulin analogues. It could 
be made available for diabetes patients receiving insulin 
therapy to assess β-cell function, via the determination of 
free insulin with PEG pre-treatment.
Authors’ Disclosures of Potential Conflicts of Interest
No potential conflict of interest relevant to this article was 
reported.
Acknowledgement
This paper was supported by a Konkuk University Medi-
cal Center Research Grant 2008, and by the Institute of Bio-
medical Science and Technology, Konkuk University.
REFERENCES
1. Sapin R. Insulin immunoassays: fast approaching 50 years of exis-
tence and still calling for standardization. Clin Chem 2007;53:810-2.
2. Radermecker RP, Renard E, Scheen AJ. Circulating insulin anti-
bodies: influence of continuous subcutaneous or intraperitoneal 
insulin infusion, and impact on glucose control. Diabetes Metab 
Res Rev 2009;25:491-501.
3. Sapin R. Insulin assays: previously known and new analytical fea-
tures. Clin Lab 2003;49:113-21.
4. Walker JM, ed. The protein protocols handbook. 2nd ed. New Jer-
sey: Humana Press, 2002:991-2.
5. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. De-
termination of free and total insulin and C-peptide in insulin-treated 
diabetics. Diabetes 1977;26:22-9.
6. Gennaro WD and Van Norman JD. Quantitation of free, total, and 
antibody-bound insulin in insulin-treated diabetics. Clin Chem 
1975; 21:873-9.
7. Armitage M, Wilkin T, Wood P, Casey C, Loveless R. Insulin auto-
antibodies and insulin assay. Diabetes 1988;37:1392-6.
8. Sapin R. Anti-insulin antibodies in insulin immunometric assays: a 
still possible pitfall. Eur J Clin Chem Clin Biochem 1997;35:365-7.
9. Sapin R. The interference of insulin antibodies in insulin immuno-
metric assays. Clin Chem Lab Med 2002;40:705-8.
10. Hanning I, Home PD, Alberti KG. Measurement of free insulin 
concentrations: the influence of the timing of extraction of insulin 
antibodies. Diabetologia 1985;28:831-5.
11. The Diabetes Control and Complications Trial Research Group. 
The effect of intensive treatment of diabetes on the development 
and progression of long-term complications in insulin-dependent 
diabetes mellitus. N Engl J Med 1993;329:977-86.
12. Jeandidier N, Boivin S, Sapin R, Rosart-Ortega F, Uring-Lambert 
B, Réville P, et al. Immunogenicity of intraperitoneal insulin infu-
sion using programmable implantable devices. Diabetologia 1995; 
38:577-84.
13. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, 
Krasner AS. Immunological responses to exogenous insulin. En-
docr Rev 2007;28:625-52.
14. Owen WE and Roberts WL. Cross-reactivity of three recombinant 
insulin analogs with five commercial insulin immunoassays. Clin 
Chem 2004;50:257-9.
15. Ibrahim F, Bagnard G, Boudou P. Differences in circulating insulin 
levels following glargine administration. Clin Biochem 2008;41: 
429-31.
16. Becker RH. Insulin glulisine complementing basal insulins: a re-
view of structure and activity. Diabetes Technol Ther 2007;9:109-
21.
17. De Meyts P. Insulin and its receptor: structure, function and evolu-
tion. Bioessays 2004;26:1351-62.
18. Devendra D, Galloway TS, Horton SJ, Evenden A, Keller U, Wilkin 
TJ. The use of phage display to distinguish insulin autoantibody 
(IAA) from insulin antibody (IA) idiotypes. Diabetologia 2003;46: 
802-9.
19. Kim HR, Lee MK, Park AJ. The -308 and -238 polymorphisms of 
the TNF-α promoter gene in type 2 diabetes mellitus. Korean J Lab 
Med 2006;26:58-63.
20. Berson SA and Yalow RS. Quantitative aspects of the reaction be-
tween insulin and insulin-binding antibody. J Clin Invest 1959;38: 
1996-2016.
21. Kahn CR and Rosenthal AS. Immunologic reactions to insulin: in-
sulin allergy, insulin resistance, and the autoimmune insulin syn-
drome. Diabetes Care 1979;2:283-95.Kim S, et al.  •  The Effects of Anti-insulin Antibodies in the Insalin Assay
www.kjlm.org     29 DOI 10.3343/kjlm.2011.31.1.22
KJLM
22. Grunfeld C. Insulin resistance: pathophysiology, diagnosis, and 
therapeutic implications. Spec Top Endocrinol Metab 1984;6:193-
240.
23. Davidson JK and DeBra DW. Immunologic insulin resistance. Dia-
betes 1978;27:307-18.
24. Arnqvist H, Olsson PO, von Schenck H. Free and total insulin as 
determined after precipitation with polyethylene glycol: analytical 
characteristics and effects of sample handling and storage. Clin 
Chem 1987;33:93-6.
25. Peluso I, Dean B, Harrison LC. Separation of free and antibody-
bound insulin in plasma using a bench ultracentrifuge (Beckman 
‘Airfuge’). Clin Chim Acta 1984;139:317-20.